3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Bicycle Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 712.84%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Bicycle Therapeutics's 3-Year ROIIC % or its related term are showing as below:
FRA:50BA's 3-Year ROIIC % is ranked better than 92.59% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs FRA:50BA: 712.84
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Bicycle Therapeutics 3-Year ROIIC % Related Terms
Bicycle Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Bicycle Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:50BA vs IFRX, ELDN, ZNTL: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Bicycle Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicycle Therapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Bicycle Therapeutics's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Bicycle Therapeutics (FRA:50BA) has a 3-Year ROIIC % of 712.84 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Bicycle Therapeutics and its competitors. According to the industry distribution chart, Bicycle Therapeutics ranks #98 out of 1322 companies in the Biotechnology industry, placing it in the top 7.4%.
Is Bicycle Therapeutics' 3-Year ROIIC % too high?
Bicycle Therapeutics' current 3-Year ROIIC % is 712.84. Based on the distribution chart, Bicycle Therapeutics ranks #98 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bicycle Therapeutics has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' 3-Year ROIIC % compare to IFRX and ELDN?
According to the Biotechnology industry distribution chart, Bicycle Therapeutics ranks #98 out of 1322 companies for 3-Year ROIIC %. This places Bicycle Therapeutics in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Bicycle Therapeutics and its competitors. Bicycle Therapeutics's current 3-Year ROIIC % is 712.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (FRA:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €11.65, compared to a current price of €3.58 — trading 69.3% below its estimated fair value. The current 3-Year ROIIC % is 712.84. Bicycle Therapeutics' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Bicycle Therapeutics (FRA:50BA), the current 3-Year ROIIC % is 712.84 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?
Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued.
The current stock price of €3.58 is trading 69.3% below its estimated GF Value™ of €11.65.
GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:50BA:
3-Year ROIIC %: 712.84
GF Value™: €11.65 vs. price of €3.58 (69.3% below fair value)
No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
56GF Score
Get the complete analysis for FRA:50BA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:50BA has been successfully added to your 
